Enhanced tumorigenesis in HTLV-1 Tax-transgenic mice deficient in interferon-gamma

Blood

Volumn 104, Issue 10, 2004, Pages 3305-3311

  Mitra Kaushik, Shibani ^b   Harding, John ^b   Hess, Jay ^b   Schreiber, Robert ^b   Ratner, Lee ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR BETA; TAX PROTEIN; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENOTYPE; HOST RESISTANCE; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KNOCKOUT GENE; LARGE GRANULAR LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNOLOGY; UPREGULATION;

EID: 8644292663     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0266     Document Type: Article

References (43)

1. Bangham CR. HTLV-1 infections. J Clin Pathol. 2000;53:581-586.
2. Blattner WA. Human retroviruses: their role in cancer. Proc Assoc Am Physicians. 1999;111:563-572.
3. Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol. 1997;15:15-37.
4. Xiao G, Cvijic ME, Fong A, et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 2001;20:6805-6815.
5. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-496.
6. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN. Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J Biol Chem. 2001;276:200-205.
7. Pise-Masison CA, Mahieux R, Radonovich M, et al. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax. AIDS Res Hum Retroviruses. 2000;16:1669-1675.
8. Giebler HA, Loring JE, van Orden K, et al. Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation. Mol Cell Biol. 1997;17:5156-5164.
9. Sun SC, Elwood J, Beraud C, Greene WC. Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Mol Cell Biol. 1994;14:7377-7384.
10. Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA. 1995;92:1057-1061.
11. Grossman WJ, Ratner L. Cytokine expression and tumorigenicity of large granular lymphocytic leukemia cells from mice transgenic for the tax gene of human T-cell leukemia virus type I. Blood. 1997;90:783-794.
12. Alexandroff AB, McIntyre CA, Porter JC, Zeuthen J, Vile RG, Taub DD. Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer. Br J Cancer. 1998;77:1806-1811.
13. Kodaka T, Uchiyama T, Umadome H, Uchino H. Expression of cytokine mRNA in leukemic cells from adult T cell leukemia patients. Jpn J Cancer Res. 1989;80:531-536.
14. Umehara F, Izumo S, Ronquillo AT, Matsumuro K, Sato E, Osame M. Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy J Neuropathol Exp Neurol. 1994;53:72-77.
15. Ichinose K, Nakamura T, Nishiura Y, et al. Characterization of adherent T cells to human endothelial cells in patients with HTLV-I-associated myelopathy. J Neural Sci. 1994;122:204-209.
16. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13:95-109.
17. Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med. 2002;196:129-134.
18. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259:1739-1742.
19. Schreiber RD, Hicks LJ, Celada A, Buchmeier NA, Gray PW. Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol. 1985;134:1609-1618.
20. Ahn EY, Pan G, Vickers SM, McDonald JM. IFN-gammaupregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer. 2002;100:445-451.
21. Andrews HN, Mullan PB, McWilliams S, et al. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem. 2002;277:26225-26232.
22. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA. 1998;95:7556-7561.
23. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1:447-456.
24. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.
25. Billiau A, Heremans H, Vermeire K, Matthys P. Immunomodulatory properties of interferon-gamma: an update. Ann N Y Acad Sci. 1998;856:22-32.
26. Hawley RG, Berger LC. Growth control mechanisms in multiple myeloma. Leuk Lymphoma. 1998;29:465-475.
27. Dai C, Krantz SB. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93:3309-3316.
28. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature. 1995;376:596-599.
29. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9:25-34.
30. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 1999;93:1612-1621.
31. Brown DA, Nelson FB, Reinherz EL, Diamond DJ. The human interferon-gamma gene contains an inducible promoter that can be transactivated by tax I and II. Eur J Immunol. 1991;21:1879-1885.
32. Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S. Demonstration of human T lymphotropic virus type I (HTLV-I) tax-specific CD8+ lymphocytes directly in peripheral blood of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by intracellular cytokine detection. J Immunol. 1998;161:482-488.
33. Owen SM, Rudolph DL, Dezzutti CS, et al. Transcriptional activation of the intercellular adhesion molecule 1 (CD54) gene by human T lymphotropic virus types I and II Tax is mediated through a palindromic response element. AIDS Res Hum Retroviruses. 1997;13:1429-1437.
34. Beatty G, Paterson Y. IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol. 2001;166:2276-2282.
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
36. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1: 27-31.
37. Qin Z, Schwartzkopff J, Pradera F, et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res. 2003;63:4095-4100.
38. Beatty GL, Paterson Y. Regulation of tumor growth by IFN-gamma in cancer immunotherapy. Immunol Res. 2001;24:201-210.
39. Hayakawa Y, Takeda K, Yagita H, et al. IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide. Blood. 2002;100:1728-1733.
40. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407-424.
41. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
42. Qin Z, Blankenstein T. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677-686.
43. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol. 2000; 164:217-222.